Seattle Genetics cancels Immunomedics deal

By Phillip Broadwith2017-05-19T10:41:00

$C:\Users\traceys\Downloads$

Source: Shutterstock

Settlement also resolves disputes with shareholders

US biotechnology firms Seattle Genetics and Immunomedics have broken off their planned licensing deal for Immunomedics’ experimental cancer antibody IMMU-132 (sacituzumab govitecan).